Comparison of Ovarian Mild Stimulation and Controlled Ovarian Stimulation in Poor Ovarian Responders
- Conditions
- Infertility
- Interventions
- Other: mild stimulation protocolOther: controlled ovarian stimulation
- Registration Number
- NCT01926210
- Lead Sponsor
- Huang Rui
- Brief Summary
This is a prospective, randomized clinical trial to compare the efficiency and safety of mild stimulation and controlled ovarian stimulation protocol on the treatment of POR. The randomization is achieved on the basis of a computer-generated randomization list in a 1:1 ratio.
- Detailed Description
500 poor ovarian responders will be equally randomized to two different ovarian stimulation protocol arms,i.e, mild ovarian stimulation(experimental arm) or controlled ovarian stimulation(control arm). In experimental arm, patients will received letrozole 5mg per day from cycle day 3 to 7 and recombinant follicle-stimulating hormone (FSH) 150 international unit (IU) on day 4 and 6. The dose of recombinant FSH is adjusted according to the ovarian response and the gonadotropin-releasing hormone(GnRH)antagonist(Cetrotide) 0.25mg per day is administrated when the estradiol level reaches 200 pg/ml and the serum luteinizing hormone (LH)level rises above 2 times of basal LH level. In control arm,patients will be stimulated with short-acting GnRH agonist long protocol. After complete downregulation is achieved through GnRH-agonist, recombinant FSH 300 IU/d is given for 5 days, then the dose of recombinant FSH is adjusted according to ovarian response.
The clinical and ongoing pregnancy rate and other secondary outcome parameters are compared between these two groups.
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- Female
- Target Recruitment
- 500
- a. Poor ovarian responders b. Normal BMI (18-25 Kg/m2) c. Regular menstruation (with cycle 23-35 days)
- a. History of repeated IVF failure (previous IVF cycle >2) b. Serious adenomyosis c. Polycystic ovary syndrome(PCOS) patients d. History of allergic to ovulation induction medicines e. Abnormal uterine cavity, i.e, intrauterine adhesion f. Attending other clinical trials in the same period. g. History of systemic disease contradictory to COH or pregnancy.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description mild ovarian stimulation mild stimulation protocol Patients are stimulated with mild ovarian stimulation protocol,i.ed, from cycle day 3 to 7, letrozole 5mg per day are administrated and recombinant FSH 150 IU are given on day 4 and 6 . On cycle day 8, serum FSH LH, and estradiol levels are measured, and after then, the dose of recombinant FSH is adjusted according to the ovarian response and the maxim recombinant FSH dose is 150 IU/d. The GnRH-antagonist (Cetrotide) 0.25mg per day is administrated when the estradiol level reaches 200 pg/ml and the serum LH level rises above 2 times of basal LH level. controlled ovarian stimulation controlled ovarian stimulation Patients are stimulated using controlled ovarian stimulation protocol,i.e., from cycle day 18-22 (day 7 after ovulation) of previous cycle, all participants are given short-acting GnRH agonist (Triptorelin 0.05mg/d) for 14 days, then after checking serum FSH, LH and estradiol to make sure that complete downregulation is achieved, exogenous gonadotropin (recombinant FSH) 300 IU/d is given for 5 days, then the dose of recombinant FSH is adjusted according to ovarian response.
- Primary Outcome Measures
Name Time Method clinical pregnancy rate 7 weeks
- Secondary Outcome Measures
Name Time Method live birth rate 10 months Number of oocytes retrieved 3 weeks Number of transferrable embryo 3 weeks normal fertilization rate 3 weeks implantation rate 7 weeks ongoing pregnancy rate 3 months Total dose of recombinant FSH consumption 3 weeks length of stimulation 3 weeks serum estradiol level 3 weeks serum LH level 3 weeks serum progesterone level 3 weeks serum FSH level 3 weeks FSH level in follicular fluid 3 weeks LH level in follicular fluid 3 weeks Estradiol level in the follicular fluid 3 weeks progesterone level in follicular fluid 3 weeks testerone level in the follicular fluid 3 weeks anti-müllerian hormone (AMH)level in follicular fluid 3 weeks Ovarian Hyperstimulation Syndrome (OHSS) rate 7 weeks
Trial Locations
- Locations (1)
sixth affiliated hospital of Sun Yet-san University
🇨🇳Guangzhou, Guangdong, China